New options in the treatment of locally advanced head and neck cancer: Role for induction chemotherapy

Cancer Treatment Reviews

Volumn 34, Issue 3, 2008, Pages 268-274

  Cruz, Juan J ^a   Ocaña, Alberto ^b   Navarro, Miguel ^a   Barco, Elvira Del ^a   Fonseca, Emilio ^a  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE ALBACETE   (Spain)

Author keywords

Cetuximab; Chemoradiotherapy; Head and neck cancer; Induction chemotherapy; Taxanes

Indexed keywords

CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; FLUOROURACIL; HYDROXYUREA; PACLITAXEL; PLATINUM; TAXANE DERIVATIVE;

ADJUVANT THERAPY; ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER CONTROL; CLINICAL TRIAL; CONTINUOUS INFUSION; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DRUG DOSE TITRATION; DRUG MEGADOSE; DRUG RESPONSE; HEAD AND NECK CANCER; HUMAN; HYPOPHARYNX CANCER; LARYNGECTOMY; LARYNX CANCER; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NECK DISSECTION; OROPHARYNX CANCER; OVERALL SURVIVAL; PROGNOSIS; REVIEW; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; HEAD AND NECK NEOPLASMS; HUMANS; META-ANALYSIS AS TOPIC; NEOADJUVANT THERAPY; RADIOTHERAPY, ADJUVANT; REMISSION INDUCTION;

EID: 43049125501     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2007.12.004     Document Type: Review

References (44)

1. Jemal A., Murray T., Ward E., et al. Cancer statistics. CA Cancer J Clin 55 1 (2005) 10-30
2. American Joint Committee on Cancer (AJCC). In: Page D.L., Fleming I.D., et al. (Eds). Manual for staging of cancer 6th ed. (2002), Springer-Verlag, Greene, FL, New York
3. Patel S.G., and Shah J.P. Diversity TNM staging of cancers of the head and neck: striving for uniformity among. CA Cancer J Clin 55 (2005) 242-258
4. Forastiere A., Koch W., Trotti A., and Sidransky D. Head and neck cancer. N Engl J Med 345 (2001) 1890-1900
5. Posner M.R., Haddad R.I., Wirth L., et al. Induction chemotherapy in locally advanced squamous cell cancer of the head and neck: evolution of the sequential treatment approach. Semin Oncol 31 (2004) 778-785
6. Garden A.S., Asper J.A., Morrison W.H., et al. Is concurrent chemoradiation the treatment of choice for all patients with Stage III or IV head and neck carcinoma?. Cancer 100 (2004) 1171-1178
7. Brizel D.M., Albers M.E., Fisher S.R., et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 338 (1998) 1798-1804
8. Forastiere A.A., Goepfert H., Maor M., et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349 (2003) 2091-2098
9. Adelstein D.J., Li Y., Adams G.L., et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 21 (2003) 92
10. Pignon J.P., Bourhis J., Domenge C., Designe L., and MACH-NC Collaborative Group. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. Meta-analysis of chemotherapy on head and neck cancer. Lancet 355 (2000) 949-955
11. Pignon J.P., Baujat B., and Bourhis J. Individual patient data meta-analyses in head and neck carcinoma: what have we learnt?. Cancer Radiother 9 (2005) 31-36
12. Adelstein D.J., Saxton J.P., Lavertu P., et al. Maximizing local control and organ preservation in stage IV squamous cell head and neck cancer with hyperfractionated radiation and concurrent chemotherapy. J Clin Oncol 20 (2002) 1405-1410
13. Denis F., Garaud P., Bardet E., et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 22 (2004) 69-76
14. El-Sayed S., and Nelson N. Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region. A meta-analysis of prospective and randomized trials. J Clin Oncol 14 (1996) 838-847
15. Browman G.P. Evidence-based recommendations against neoadjuvant chemotherapy for routine management of patients with squamous cell head and neck cancer. Cancer Invest 12 (1994) 662-670
16. Paccagnella A., Orlando A., Marchiori C., et al. Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst 86 (1994) 265-272
17. Domenge C., Hill C., Lefebvre J.L., et al. Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe d'Etude des Tumeurs de la Tete et du Cou (GETTEC). Br J Cancer 83 (2000) 1594-1598
18. Ensley J.F., Jacobs J.R., Weaver A., et al. Correlation between response to cisplatinum-combination chemotherapy and subsequent radiotherapy in previously untreated patients with advanced squamous cell cancers of the head and neck. Cancer 54 (1984) 811-814
19. Jacobs C., Goffinet D.R., Goffinet L., et al. Chemotherapy as a substitute for surgery in the treatment advanced resectable head and neck cancer. A report from the Northern California Oncology Group. Cancer 60 (1987) 1178-1183
20. Hitt R., Paz-Ares L., Brandariz A., et al. Induction chemotherapy with paclitaxel, cisplatin and 5-fluorouracil for squamous cell carcinoma of the head and neck: long-term results of a phase II trial. Ann Oncol 13 (2002) 1665-1673
21. Posner M.R., Glisson B., Frenette G., et al. Multicenter phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck. J Clin Oncol 19 (2001) 1096-1104
22. Vermorken J.B., Remenar E., and Van Herpen C. Standard cisplatin/infusional 5-fluorouracil (PF) vs. docetaxel (T) plus PF (TPF) as neoadjuvant chemotherapy for nonresectable locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN): a phase III trial of the EORTC Head and Neck Cancer Group (EORTC #24971). Proc Am Soc Clin Oncol (2004) (Abstract 5508)
23. Hitt R., Lopez-Pousa A., Martinez-Trufero J., et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 23 (2005) 8636-8645
24. Vermorken J.B., Remenar E., Van Herpen C., et al. Cisplatin, fluoracil and docetaxel in unresectable head and neck cancer. N Engl J Med 357 (2007) 1695-1704
25. Bernier J., Coens C., Remenar E., et al. Impact on quality of life (QoL) of the addition of docetaxel (T) to neoadjuvant cisplatin plus 5-fluorouracil treatment in patients with locally advanced unresectable squamous cell carcinoma of the head and neck (SCCHN): EORTC study 24971. Proc Am Soc Clin Oncol 24 (2006) 285s (Abstract 5522)
26. Calais G., Pointreau Y., Alfonsi M., et al. randomized phase III trial comparing induction chemotherapy using cisplatin (P) fluoracil (F) with or without docetaxel (T) for organ preservation in hipopharynx and larynx cancer. preliminary results of GORTEC 2000-01. Proc Am Soc Clin Oncol 24 (2006) 281s (Abstract 5506)
27. Vokes E.E., Kies M.S., Haraf D.J., et al. Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer. J Clin Oncol 18 (2000) 1652-1661
28. Worden FP, Wolf G, Eisbruch A, et al. Chemo-selection of patients (pts) for organ preservation in advanced laryngeal cancer: Failure of chemotherapy (CT) as the sole treatment for complete histologic responders (CHR) to neoadjuvant chemotherapy. J Clin Oncol, 2006 ASCO Annual Meeting Proceedings Part I; 24, No. 18S (June 20 Supplement): 5560.
29. Posner M.R., Colevas A.D., and Tishler R.B. The role of induction chemotherapy in the curative treatment of squamous cell cancer of the head and neck. Semin Oncol 27 (2000) 13-24
30. Haddad R.I., Wirth L., and Posner M.R. Integration of chemotherapy in the curative treatment of locally advanced head and neck cancer. Expert Rev Anticancer Ther 3 (2003) 331-338
31. Machtay M., Rosenthal D.I., Hershock D., et al. Organ preservation therapy using induction plus concurrent chemoradiation for advanced resectable oropharyngeal carcinoma: a University of Pennsylvania Phase II Trial. J Clin Oncol 20 (2002) 3964-3971
32. Vokes E.E., Stenson K., Rosen F.R., et al. Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer. J Clin Oncol 21 (2003) 320-326
33. Cmelak A., Murphy B.A., Burkey B., et al. Induction chemotherapy (IC) followed by concurrent chemoradiation (CCR) for organ preservation (OP) in locally advanced squamous head and neck cancer (SHNC): Results of a Phase II trial. Proc Am Soc Clin Oncol 22 (2003) (Abstract 2016)
34. Cmelak A.J., Li B., Murphy B., et al. Locally advanced resectable larynx (L) or oropharynx (OP) cancer: update results of organ preservation trial ECOG 2399. Proc Am Soc Clin Oncol (2006) (Abstract 5527)
35. Hainsworth J.D., Meluch A.A., McClurkan S., et al. Induction paclitaxel, carboplatin, and infusional 5-FU followed by concurrent radiation therapy and weekly paclitaxel/carboplatin in the treatment of locally advanced head and neck cancer: a phase II trial of the Minnie Pearl Cancer Research Network. Cancer J 8 (2002) 311-321
36. Posner M.R., Hershock D.M., and Blajman C.R. Cisplatin, fluoracil alone or with docetaxel in head and neck cancer. N Engl J Med 357 (2007) 1705-1715
37. Paccagnella A., Buffoli A., Koussis H., et al. Randomized phase II trial of concomitant CT/RT versus TPF followed by concomitant CT/RT in locally advanced squamus cell carcinoma of the head and neck (LAHNC). Proc Am Soc Clin Oncol (2006) (Abstract 5518)
38. Hitt R., Grau J., and Lopez-Pousa A. Phase II/III trial of induction chemotherapy(ICT) with cisplatin/5-fluorouracil (PF) vs. docetaxel (T) plus PF (TPF) followed by chemoradiotherapy (CRT) vs. CRT for unresectable locally advanced head and neck cancer (LAHNC). Proc Am Soc Clin Oncol (2006) (Abstract 5515)
39. Hitt R., Grau J., Lopez-Pousa A., et al. Phase II/III Trial of induction chemotherapy(ICT) with cisplatin/5-fluorouracil (PF) vs. docetaxel (T) plus PF (TPF) followed by chemoradiotherapy (CRT) vs. CRT for unresectable locally advanced head and neck cancer (LAHNC). Proc Am Soc Clin Oncol (2005) (Abstract 5578)
40. Baselga J., Trigo J.M., Bourhis J., et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 23 (2005) 5568-5577
41. Herbst R.S., Arquette M., Shin D.M., et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 23 (2005) 5578-5587
42. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354 (2006) 567-578
43. Burtness B., Goldwasser M.A., Flood W., et al. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 23 (2005) 8646-8654
44. Wanebo HJ, Ghebremichael M, Burtness B, Spencer S, Ridge J, Forastiere A, et al. Phase II evaluation of cetuximab (C225) combined with induction paclitaxel and carboplatin followed by C225, paclitaxel, carboplatin, and radiation for stage III/IV operable squamous cancer of the head and neck (ECOG, E2303). J Clin Oncol ASCO Annual Meeting Proceedings Part I. 2007; 25, No. 18S (June 20 Supplement): 6015.